scispace - formally typeset
Search or ask a question
Institution

Guy's and St Thomas' NHS Foundation Trust

HealthcareLondon, United Kingdom
About: Guy's and St Thomas' NHS Foundation Trust is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 7686 authors who have published 9631 publications receiving 399353 citations. The organization is also known as: Guy's and St Thomas' National Health Service Foundation Trust & Guy's and St Thomas' National Health Service Trust.


Papers
More filters
Journal ArticleDOI
Kristen N. Stevens1, Celine M. Vachon1, Adam M. Lee1, Susan L. Slager1, Timothy G. Lesnick1, Curtis Olswold1, Peter A. Fasching2, Penelope Miron3, Diana Eccles4, Jane Carpenter5, Andrew K. Godwin6, Christine B. Ambrosone7, Robert Winqvist7, Hiltrud Brauch8, Marjanka K. Schmidt9, Angela Cox10, Simon S. Cross10, Elinor J. Sawyer11, Arndt Hartmann12, Matthias W. Beckmann12, Rüdiger Schulz-Wendtland12, Arif B. Ekici12, William J. Tapper4, S Gerty4, Lorraine Durcan4, Nikki Graham4, Rebecca Hein13, Stephan Nickels13, Dieter Flesch-Janys14, Judith Heinz14, Hans-Peter Sinn15, Irene Konstantopoulou16, Florentia Fostira16, Dimitrios Pectasides16, Athanasios M. Dimopoulos16, George Fountzilas17, Christine L. Clarke5, Rosemary L. Balleine18, Janet E. Olson1, Zachary S. Fredericksen1, Robert B. Diasio1, Harsh B. Pathak19, Eric A. Ross19, Jo Ellen Weaver19, Thomas Rüdiger, Asta Försti20, Asta Försti13, Thomas Dünnebier13, Foluso O. Ademuyiwa7, Swati Kulkarni7, Katri Pylkäs, Arja Jukkola-Vuorinen21, Yon Ko, Erik Van Limbergen22, Hilde Janssen22, Julian Peto23, Olivia Fletcher, Graham G. Giles24, Laura Baglietto24, Senno Verhoef9, Ian Tomlinson25, Veli-Matti Kosma26, Jonathan Beesley27, Dario Greco28, Carl Blomqvist28, Astrid Irwanto29, Jianjun Liu29, Fiona M. Blows30, Sarah-Jane Dawson30, Sara Margolin31, Arto Mannermaa26, Nicholas G. Martin27, Grant W. Montgomery27, Diether Lambrechts22, Diether Lambrechts32, Isabel dos Santos Silva23, Gianluca Severi24, Ute Hamann13, Ute Hamann20, Paul D.P. Pharoah30, Douglas F. Easton, Jenny Chang-Claude12, Drakoulis Yannoukakos15, Heli Nevanlinna28, Xianshu Wang1, Fergus J. Couch1 
TL;DR: Six single-nucleotide polymorphisms are identified, significantly associated with the risk of triple-negative breast cancer, providing convincing evidence of genetic susceptibility for triple- negative breast cancer.
Abstract: Triple-negative breast cancers are an aggressive subtype of breast cancer with poor survival, but there remains little known about the etiologic factors that promote its initiation and development. Commonly inherited breast cancer risk factors identified through genome-wide association studies display heterogeneity of effect among breast cancer subtypes as defined by the status of estrogen and progesterone receptors. In the Triple Negative Breast Cancer Consortium (TNBCC), 22 common breast cancer susceptibility variants were investigated in 2,980 Caucasian women with triple-negative breast cancer and 4,978 healthy controls. We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer. Together, our results provide convincing evidence of genetic susceptibility for triple-negative breast cancer.

118 citations

Journal ArticleDOI
TL;DR: Testing the hypothesis that sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a correlative marker in metastatic clear cell renal cancer (mRCC) yields prognostic significant data found responses occur in the majority of patients after 4 weeks of therapy but it is not until 16 weeks when the results become prognostically significant.
Abstract: Purpose: To test the hypothesis that sequential 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is a correlative marker in metastatic clear cell renal cancer (mRCC), patients were treated with sunitinib. Three sequential scans were conducted to determine whether the timing of the investigation was relevant. Experimental Design: Forty-four untreated mRCC patients were enrolled into this prospective phase II study. 18 F-FDG-PET/CT scans were conducted before ( n = 44) and after 4 weeks ( n = 43) and 16 weeks ( n = 40) of sunitinib given at standard doses. The primary endpoint was to correlate FDG-PET/CT response (20% reduction in SUV max ) at 4 and 16 weeks with overall survival (OS). Results: Forty-three (98%) patients had FDG-PET/CT avid lesions at diagnosis (median SUV max = 6.8, range: max and an increased number of PET-positive lesions correlated with shorter OS [HR: 3.30 (95% CI: 1.36–8.45) and 3.67 (95% CI: 1.43–9.39), respectively]. After 4 weeks of sunitinib, a metabolic response occurred in 24 (57%) patients, but this did not correlate with progression-free survival (HR for responders = 0.87; 95% CI: 0.40–1.99) or OS (HR for responders = 0.80; 95% CI: 0.34–1.85). After 16 weeks of treatment, disease progression on FDG-PET/CT occurred in 28% ( n = 12) patients which correlated with a decreased OS and PFS [HR = 5.96 (95% CI: 2.43–19.02) and HR = 12.13 (95% CI: 3.72–46.45), respectively]. Conclusions: Baseline FDG-PET/CT yields prognostic significant data. FDG-PET/CT responses occur in the majority of patients after 4 weeks of therapy; however, it is not until 16 weeks when the results become prognostically significant. Clin Cancer Res; 17(18); 6021–8. ©2011 AACR .

118 citations

Journal ArticleDOI
01 Nov 2007-Thorax
TL;DR: Patients with active TB have lower serum vitamin D concentrations than contacts from similar ethnic and social backgrounds and with comparable dietary intake and sun exposure, and do not show the expected seasonal variation.
Abstract: Background: As well as its role in the regulation of calcium metabolism, vitamin D is an immunoregulatory hormone. Epidemiological evidence also suggests a link between vitamin D deficiency and tuberculosis (TB). A study was undertaken to examine serum vitamin D concentrations before treatment in patients with active TB and their contacts from the same ethnic and social background and to investigate the relative contributions of diet and sunlight exposure. Methods: Serum vitamin D concentrations were measured before treatment in 178 patients with active TB and 130 healthy contacts. The prevalence of vitamin D deficiency and its relation to skin colour, month of estimation and TB diagnosis were determined. 35 patients and 35 frequency-matched contacts completed dietary and sun exposure questionnaires to determine the relative contribution of these to serum vitamin D concentrations. Results: There was a statistically significant difference in serum vitamin D concentrations between patients and contacts (20.1 vs 30.8 nmol/l, 95% CI 7.1 to 14.3; p r = 0.42, p = 0.016) than controls ( r = 0.13, p>0.1). There was no difference in sunlight exposure between the groups. Conclusions: Patients with active TB have lower serum vitamin D concentrations than contacts from similar ethnic and social backgrounds and with comparable dietary intake and sun exposure, and do not show the expected seasonal variation. These observations indicate that other factors are contributing to vitamin D deficiency in patients with TB and suggest abnormal handling of this vitamin.

118 citations

Journal ArticleDOI
TL;DR: The evidence suggesting that a reduction in the functional capacity of different Treg populations contributes to disease development in type 1 diabetes is highlighted.
Abstract: Type 1 diabetes is an autoimmune disease characterised by the destruction of insulin producing beta cells in the pancreas. Whilst it remains unclear what the original triggering factors for this destruction are, observations from the natural history of human type 1 diabetes, including incidence rates in twins, suggest that the disease results from a combination of genetic and environmental factors. Whilst many different immune cells have been implicated, including members of the innate and adaptive immune systems, a view has emerged over the past 10 years that beta cell damage is mediated by the combined actions of CD4+ and CD8+ T cells with specificity for islet autoantigens. In health, these potentially pathogenic T cells are held in check by multiple regulatory mechanisms, known collectively as ‘immunological tolerance’. This raises the question as to whether type 1 diabetes develops, at least in part, as a result of a defect in one or more of these control mechanisms. Immunological tolerance includes both central mechanisms (purging of the T cell repertoire of high-affinity autoreactive T cells in the thymus) and peripheral mechanisms, a major component of which is the action of a specialised subpopulation of T cells, known as regulatory T cells (Tregs). In this review, we highlight the evidence suggesting that a reduction in the functional capacity of different Treg populations contributes to disease development in type 1 diabetes. We also address current controversies regarding the putative causes of this defect and discuss strategies to correct it as a means to reduce or prevent islet destruction in a clinical setting.

118 citations

Journal ArticleDOI
TL;DR: Data suggest that it is possible to discriminate between biologics to inform clinical practice and decision making and that trial performance may not equate to real-world performance, and so results need to be considered alongside real- world, long-term safety and effectiveness data.

118 citations


Authors

Showing all 7765 results

NameH-indexPapersCitations
Christopher J L Murray209754310329
Bruce M. Psaty1811205138244
Giuseppe Remuzzi1721226160440
Mika Kivimäki1661515141468
Simon I. Hay165557153307
Theo Vos156502186409
Ali H. Mokdad156634160599
Steven Williams144137586712
Igor Rudan142658103659
Mohsen Naghavi139381169048
Christopher D.M. Fletcher13867482484
Martin McKee1381732125972
David A. Jackson136109568352
Graham G. Giles136124980038
Yang Liu1292506122380
Network Information
Related Institutions (5)
University Medical Center Groningen
30.3K papers, 967K citations

93% related

Royal Free Hospital
15.7K papers, 651.9K citations

93% related

John Radcliffe Hospital
23.6K papers, 1.4M citations

92% related

Radboud University Nijmegen Medical Centre
12.6K papers, 659.2K citations

92% related

Leiden University Medical Center
38K papers, 1.6M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202316
202298
20211,488
20201,123
2019829
2018767